Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 9 | 2024 | 118 | 2.770 |
Why?
|
| Exercise | 13 | 2023 | 919 | 2.120 |
Why?
|
| Amylose | 2 | 2024 | 6 | 1.670 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 202 | 1.280 |
Why?
|
| Exercise Therapy | 8 | 2023 | 102 | 1.240 |
Why?
|
| Resistance Training | 3 | 2012 | 20 | 1.140 |
Why?
|
| Starch | 1 | 2024 | 62 | 0.900 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 193 | 0.850 |
Why?
|
| Blood Pressure | 4 | 2019 | 522 | 0.810 |
Why?
|
| Testosterone | 2 | 2012 | 111 | 0.720 |
Why?
|
| Cardiac Rehabilitation | 5 | 2023 | 67 | 0.700 |
Why?
|
| Weight Lifting | 3 | 2012 | 12 | 0.670 |
Why?
|
| Heart Rate | 5 | 2023 | 308 | 0.610 |
Why?
|
| Occupations | 1 | 2018 | 52 | 0.600 |
Why?
|
| Oxygen Consumption | 4 | 2022 | 205 | 0.600 |
Why?
|
| Oxidative Stress | 5 | 2024 | 282 | 0.560 |
Why?
|
| Universities | 1 | 2018 | 152 | 0.560 |
Why?
|
| Caloric Restriction | 3 | 2021 | 16 | 0.510 |
Why?
|
| Middle Aged | 22 | 2024 | 16542 | 0.490 |
Why?
|
| Vascular Stiffness | 2 | 2014 | 14 | 0.480 |
Why?
|
| Exercise Test | 4 | 2023 | 237 | 0.450 |
Why?
|
| Vascular Resistance | 1 | 2014 | 44 | 0.450 |
Why?
|
| Body Composition | 3 | 2012 | 155 | 0.440 |
Why?
|
| Hypotension | 2 | 2017 | 47 | 0.430 |
Why?
|
| Metabolic Syndrome | 2 | 2012 | 149 | 0.430 |
Why?
|
| Adult | 18 | 2024 | 15972 | 0.430 |
Why?
|
| Biomarkers | 6 | 2024 | 1214 | 0.430 |
Why?
|
| Aged | 16 | 2024 | 13596 | 0.430 |
Why?
|
| Physical Exertion | 2 | 2022 | 78 | 0.410 |
Why?
|
| Lower Extremity | 2 | 2012 | 146 | 0.400 |
Why?
|
| Time Factors | 10 | 2021 | 3621 | 0.390 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2012 | 10 | 0.390 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 36 | 0.390 |
Why?
|
| Double-Blind Method | 3 | 2024 | 684 | 0.370 |
Why?
|
| Male | 23 | 2024 | 27951 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 677 | 0.350 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 831 | 0.330 |
Why?
|
| Humans | 31 | 2024 | 60081 | 0.330 |
Why?
|
| Overweight | 1 | 2012 | 249 | 0.330 |
Why?
|
| Weight Loss | 1 | 2012 | 264 | 0.330 |
Why?
|
| Muscle, Skeletal | 2 | 2012 | 679 | 0.310 |
Why?
|
| Workplace | 2 | 2019 | 180 | 0.290 |
Why?
|
| Occupational Health | 2 | 2019 | 186 | 0.280 |
Why?
|
| Kidney Diseases | 1 | 2008 | 160 | 0.280 |
Why?
|
| Female | 20 | 2024 | 31226 | 0.270 |
Why?
|
| Physical Endurance | 3 | 2020 | 48 | 0.270 |
Why?
|
| Heart Diseases | 2 | 2019 | 206 | 0.260 |
Why?
|
| Pilot Projects | 6 | 2023 | 930 | 0.260 |
Why?
|
| Smoking Cessation | 3 | 2019 | 538 | 0.250 |
Why?
|
| Cresols | 1 | 2024 | 5 | 0.240 |
Why?
|
| Sulfuric Acid Esters | 1 | 2024 | 6 | 0.240 |
Why?
|
| Indican | 1 | 2024 | 3 | 0.240 |
Why?
|
| Anaerobic Threshold | 1 | 2004 | 10 | 0.230 |
Why?
|
| Massachusetts | 5 | 2019 | 2119 | 0.230 |
Why?
|
| Feces | 1 | 2024 | 97 | 0.230 |
Why?
|
| Smoking | 2 | 2019 | 837 | 0.220 |
Why?
|
| Clinical Protocols | 1 | 2004 | 137 | 0.210 |
Why?
|
| Fear | 1 | 2023 | 67 | 0.210 |
Why?
|
| Inflammation | 2 | 2020 | 1111 | 0.200 |
Why?
|
| Self Efficacy | 1 | 2023 | 199 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2024 | 249 | 0.200 |
Why?
|
| Coronary Disease | 1 | 2023 | 251 | 0.200 |
Why?
|
| Muscle Strength | 2 | 2012 | 37 | 0.200 |
Why?
|
| Hospitalization | 2 | 2019 | 1304 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 11 | 0.190 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 29 | 0.190 |
Why?
|
| DNA, Mitochondrial | 1 | 2021 | 78 | 0.180 |
Why?
|
| Treatment Outcome | 6 | 2021 | 5266 | 0.180 |
Why?
|
| Zea mays | 1 | 2020 | 23 | 0.180 |
Why?
|
| Analysis of Variance | 2 | 2020 | 576 | 0.180 |
Why?
|
| Walking | 3 | 2017 | 230 | 0.170 |
Why?
|
| Adipokines | 1 | 2020 | 28 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 685 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 95 | 0.170 |
Why?
|
| Athletes | 2 | 2012 | 97 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 158 | 0.160 |
Why?
|
| Health Promotion | 2 | 2019 | 490 | 0.150 |
Why?
|
| Running | 2 | 2012 | 80 | 0.150 |
Why?
|
| Accelerometry | 1 | 2018 | 59 | 0.150 |
Why?
|
| Young Adult | 3 | 2012 | 4398 | 0.140 |
Why?
|
| New England | 1 | 2018 | 268 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2011 | 83 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 2615 | 0.140 |
Why?
|
| Physical Fitness | 2 | 2011 | 92 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2019 | 373 | 0.130 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 57 | 0.130 |
Why?
|
| Adiposity | 2 | 2017 | 78 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 253 | 0.130 |
Why?
|
| Kidney Function Tests | 2 | 2012 | 33 | 0.130 |
Why?
|
| Decision Making | 1 | 2019 | 394 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2018 | 531 | 0.120 |
Why?
|
| Kidney | 1 | 2017 | 397 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 455 | 0.110 |
Why?
|
| Hypertension | 1 | 2019 | 603 | 0.110 |
Why?
|
| Circadian Rhythm | 1 | 2017 | 371 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2360 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 869 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 105 | 0.100 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 56 | 0.100 |
Why?
|
| Football | 1 | 2012 | 16 | 0.100 |
Why?
|
| Prescriptions | 2 | 2022 | 33 | 0.100 |
Why?
|
| Electromyography | 1 | 2012 | 87 | 0.100 |
Why?
|
| Waist Circumference | 1 | 2012 | 53 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 105 | 0.090 |
Why?
|
| Diet, Reducing | 1 | 2011 | 31 | 0.090 |
Why?
|
| Triglycerides | 1 | 2012 | 242 | 0.090 |
Why?
|
| Creatine Kinase | 1 | 2011 | 41 | 0.090 |
Why?
|
| Lactates | 1 | 2011 | 28 | 0.090 |
Why?
|
| Human Growth Hormone | 1 | 2011 | 18 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 361 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 72 | 0.090 |
Why?
|
| Reference Values | 1 | 2011 | 319 | 0.090 |
Why?
|
| Actinin | 1 | 2010 | 9 | 0.090 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2010 | 39 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2011 | 188 | 0.080 |
Why?
|
| Sports | 1 | 2010 | 92 | 0.080 |
Why?
|
| Adolescent | 2 | 2012 | 5944 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2011 | 351 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2012 | 892 | 0.070 |
Why?
|
| Risk Factors | 1 | 2017 | 5090 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2006 | 27 | 0.060 |
Why?
|
| Inpatients | 2 | 2019 | 300 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1471 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2008 | 744 | 0.060 |
Why?
|
| Yoga | 1 | 2004 | 15 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2480 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 171 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2004 | 186 | 0.060 |
Why?
|
| Muscles | 1 | 2004 | 172 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1191 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 268 | 0.050 |
Why?
|
| Hand Strength | 1 | 2002 | 29 | 0.050 |
Why?
|
| Pain | 1 | 2004 | 407 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 101 | 0.050 |
Why?
|
| Gait | 1 | 2002 | 117 | 0.050 |
Why?
|
| United States | 3 | 2021 | 7622 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 170 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 365 | 0.040 |
Why?
|
| Adiponectin | 1 | 2020 | 34 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 1565 | 0.040 |
Why?
|
| Leptin | 1 | 2020 | 79 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 43 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 294 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 140 | 0.040 |
Why?
|
| Intention | 1 | 2018 | 66 | 0.040 |
Why?
|
| F2-Isoprostanes | 1 | 2017 | 3 | 0.040 |
Why?
|
| Albuminuria | 1 | 2017 | 24 | 0.040 |
Why?
|
| Creatinine | 1 | 2017 | 123 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 628 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 793 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 661 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 419 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 309 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 381 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 352 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1267 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 400 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2010 | 1064 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 569 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2018 | 451 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 719 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 868 | 0.020 |
Why?
|
| Fluoroimmunoassay | 1 | 2011 | 2 | 0.020 |
Why?
|
| Athletic Performance | 1 | 2011 | 7 | 0.020 |
Why?
|
| Jamaica | 1 | 2010 | 2 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 129 | 0.020 |
Why?
|
| Genotype | 1 | 2010 | 628 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 6147 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2095 | 0.020 |
Why?
|
| Vasodilation | 1 | 2006 | 38 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 11 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 338 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 19739 | 0.010 |
Why?
|